{
    "clinical_study": {
        "@rank": "63707", 
        "acronym": "BM019-Registry", 
        "brief_summary": {
            "textblock": "The purpose of this enhanced surveillance study (\"ESS\") is to collect information regarding\n      chronic adverse events that are possibly related to the ExAblate\u00ae System (\"ExAblate\") that\n      are received by InSightec (\"InSightec\") following PMA approval.  This study will examine\n      adverse events reported in patients undergoing the device procedure for the first two years\n      of commercial experience.  Other relevant data may be collected as well."
        }, 
        "brief_title": "ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain Resulting From Bone Metastases", 
        "condition_browse": {
            "mesh_term": [
                "Bone Neoplasms", 
                "Neoplasm Metastasis", 
                "Bone Marrow Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This proposed Registry will be performed in full compliance with all HIPAA rules and their\n      implementations at potential participating sites.  All patients planned to undergo the\n      ExAblate procedure in a commercial setting after PMA approval will be offered a consent so\n      they can be included in the ESS.  Non-consenting patients will not be included in the ESS.\n      However, information regarding the total number of subjects treated at each participating\n      site with the device will also be collected.\n\n      InSightec will set up a (password protected) EDC database for the sites to enter the\n      information of participating subjects treated with the ExAblate device from all U.S. sites\n      using the ExAblate procedure for the bone metastases indication.  This will occur for a\n      total duration of 2 years following device approval.  It should be noted that any adverse\n      event that meets the Medical Device Report (\"MDR\") definition will be reported as an MDR as\n      well.\n\n      There will be no control group.  Reporting to FDA will occur at six-month intervals for the\n      first two-years after PMA approval."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "This study collects safety data on patient treatments performed commercially under the FDA\n        approved labeling.\n\n          -  Eligibility is as per approved device indication.\n\n          -  All registry-consented patients who undergo commercial ExAblate procedure for bone\n             mets palliation after device approval."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All consented patients from all participating US sites who receive the commercial ExAblate\n        procedure during the first year after approval will be included.  This study/registry will\n        examine treatment background information such adverse events, primary cancer type,\n        treatment frequency, etc., reported in patients undergoing the device procedure for the\n        first two years of commercial experience."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01834937", 
            "org_study_id": "BM019-Registry", 
            "secondary_id": "BM019-Registry"
        }, 
        "intervention": {
            "description": "Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.", 
            "intervention_name": "ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ExAblate", 
            "MRgFUS", 
            "Bone Metastases", 
            "Pain Palliation"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mbrooks@coh.org", 
                    "last_name": "Maria Brookes", 
                    "phone": "626-256-4673", 
                    "phone_ext": "64402"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Jeff Wong, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Fizaa@stanford.edu", 
                    "last_name": "Fizaa Ahmed", 
                    "phone": "650-725-6409"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University"
                }, 
                "investigator": {
                    "last_name": "Pejman Ghanouni, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sathre@mayo.edu", 
                    "last_name": "Connie Sathre", 
                    "phone": "507-538-0540"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "David Woodrum, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "PD9D@hscmail.mcc.virginia.edu", 
                    "last_name": "Parchayi Dalal"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "University of Virginia"
                }, 
                "investigator": {
                    "last_name": "James Larner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This study is designed to collect safety data during the first two years of commercial use of ExAblate MRgFUS treatment for palliation of pain resulting from bone metastases.", 
            "measure": "Adverse Events", 
            "safety_issue": "No", 
            "time_frame": "Two Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01834937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "InSightec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InSightec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "4 Months", 
        "verification_date": "April 2014"
    }
}